289 related articles for article (PubMed ID: 37495552)
21. Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis.
Martinez-Molina C; Diaz-Torne C; Park HS; Feliu A; Vidal S; Corominas H
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541086
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
[TBL] [Abstract][Full Text] [Related]
24. JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W; King BA
J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
[TBL] [Abstract][Full Text] [Related]
25. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
[TBL] [Abstract][Full Text] [Related]
26. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
28. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Sener S; Cam V; Ozen S; Batu ED
Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis.
Bridgeman SG; Martino AK; Strowd LC
Expert Opin Pharmacother; 2023; 24(18):2153-2159. PubMed ID: 38018382
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
32. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.
Lim JH; Kwon SH; Lew BL
Int J Dermatol; 2024 Feb; 63(2):196-200. PubMed ID: 38058206
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
[TBL] [Abstract][Full Text] [Related]
34. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
35. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
36. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
[TBL] [Abstract][Full Text] [Related]
40. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
